About Genomic Prediction
Genomic Prediction is a precision medicine company specializing in advanced genetic testing and polygenic risk assessment for reproductive health. The company develops and offers preimplantation genetic testing services that utilize polygenic risk scores to evaluate embryos during in vitro fertilization (IVF) procedures. Their technology analyzes multiple genetic variants simultaneously to assess risk for complex conditions and traits, going beyond traditional single-gene disorder screening. Genomic Prediction's services are designed to provide prospective parents and fertility clinics with comprehensive genetic information to support informed decision-making during the embryo selection process. The company operates at the intersection of genomics, artificial intelligence, and reproductive medicine, applying computational methods to interpret genetic data and predict health outcomes. Their approach represents an evolution in preimplantation genetic testing, incorporating polygenic risk assessment alongside traditional genetic screening methods to provide a more complete picture of embryo health potential.
Clinical Focus
Medical conditions and clinical areas addressed by Genomic Prediction.
Who It Serves
Social & Media
Follow on
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.